Skip to main content
. 2012 Nov 30;6:1987–1996. doi: 10.2147/OPTH.S35715

Table 1.

Characteristics and baseline pathogens of bacterial conjunctivitis patients infected with P. aeruginosa across four clinical studies

Patient age/gender Baseline pathogen(s) at or above threshold criteria Besifloxacin MICa (μg/mL) Treatment allocation Treatment regimen/study
OD OS
72-year-old female P. aeruginosa (150 cfu/mL)
S. aureus (750 cfu/mL)		 NS 2 Vehicle TID 5 days
Tepedino et al26
50-year-old female P. aeruginosa (5 cfu/mL)
S. marcescens (35 cfu/mL)		 No growth 4 BES TID 5 days
Tepedino et al26
40-year-old female NS P. aeruginosa (250 cfu/mL)
S. marcescens (125 cfu/mL)		 2 BES TID 5 days
Tepedino et al26
62-year-old female No growth P. aeruginosa (1750 cfu/mL) 2 BES TID 5 days
McDonald et al27
86-year-old female NS E. faecalis (450 cfu/mL)
P. aeruginosa (30 cfu/mL)
S. aureus (1000 cfu/mL)
S. epidermidis (700 cfu/mL)		 2 MOX TID 5 days
McDonald et al27
80-year-old female* S. aureus (2125 cfu/mL) NS 1 MOX TID 5 days
McDonald et al27
63-year-old female P. aeruginosa (30 cfu/mL)
S. epidermidis (575 cfu/mL)
S. pneumoniae (140 cfu/mL)		 S. epidermidis (240 cfu/mL)
S. pneumoniae (2875 cfu/mL)		 2 MOX TID 5 days
McDonald et al27
3-year-old female† S. pneumoniae (100 cfu/mL)
C. pseudodiphtheriticum (925 cfu/mL)		 S. pneumoniae (5675 cfu/mL)
S. epidermidis (65 cfu/mL)		 2 BES TID 5 days
McDonald et al27
64-year-old female NS P. aeruginosa (6000 cfu/mL) 2 MOX TID 5 days
McDonald et al27
81-year-old male No growth P. aeruginosa (1350 cfu/mL) 1 BES TID 5 days
McDonald et al27
2-year-old male P. aeruginosa (50 cfu/mL) No growth 2 BES BID 3 days
DeLeon et al29

Notes:

*

P. aeruginosa cultured at visit 3 (140,000 cfu/mL, OD);

†

P. aeruginosa cultured at visit 2 (100 cfu/mL, OS) and at visit 3 (15 cfu/mL, OD);

a

minimum inhibitory concentration (MIC) of besifloxacin needed to inhibit the growth of the P. aeruginosa isolate from that patient.

Abbreviations: BID, twice daily; TID, three times daily; NS, no conjunctival sample collected; BES, besifloxacin ophthalmic suspension 0.6%; MIC, minimum inhibitory concentration; MOX, moxifloxacin ophthalmic solution 0.5%; P. aeruginosa, Pseudomonas aeruginosa; C. pseudodiphtheriticum, Corynebacterium pseudodiphtheriticum; S. epidermidis, Staphylococcus epidermidis; S. pneumoniae, Streptococcus pneumoniae; S. marcescens, Serratia marcescens; E. faecalis, Enterococcus faecalis; S.aureus, Staphylococcus aureus.